Study of BMS-986504 for solid tumors with MTAP deletion
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumor cancer with a change in the MTAP gene (known as homozygous deletion), found in a tumor tissue test.
- You have tried standard treatments for your cancer and they stopped working, or no standard treatment is available or right for you.
- You have at least one tumor that can be measured on a scan with RECIST or mRECIST criteria.
- Your blood clotting test results (INR and aPTT) are within certain limits, with slightly higher levels allowed if your cancer has spread to the liver.
- You are physically active enough to have a performance status of 0 or 1 on the ECOG scale, meaning you can do daily activities without help or with minimal help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.